InMed Pharmaceuticals (INM) Depreciation and Depletion (2019 - 2025)

InMed Pharmaceuticals' Depreciation and Depletion history runs 7 years deep, the most recent figure standing at $12206.0 for Q2 2025.

• On a quarterly basis, Depreciation and Depletion rose 124.37% year-over-year to $12206.0 in Q2 2025; TTM through Jun 2025 was $50204.0, a 5.16% increase from a year earlier, with the FY2025 full-year figure at $50204.0, up 5.16% from the prior year.
• Depreciation and Depletion steadied at $12206.0 in Q2 2025 per INM's latest filing, from $12203.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $14242.0 in Q4 2023 and bottomed at $3633.0 in Q1 2021.
• The 5-year median for Depreciation and Depletion is $10586.0 (2023), against an average of $9859.8.
• Across the five-year window, Depreciation and Depletion plunged 86.48% in 2021 and surged 124.37% in 2025, its largest moves.
• Year by year, Depreciation and Depletion stood at $6246.0 in 2021, then climbed by 28.98% to $8056.0 in 2022, then surged by 76.79% to $14242.0 in 2023, then decreased by 14.27% to $12209.0 in 2024, then declined by 0.02% to $12206.0 in 2025.
• Per Business Quant, the three latest INM Depreciation and Depletion figures stand at $12206.0 (Q2 2025), $12203.0 (Q1 2025), and $12209.0 (Q4 2024).